Globus Medical Rises After Securing European Approval for Excelsius3D Imaging System

Globus Medical, Inc. (NYSE:GMED) shares gained in after-hours trading Thursday after the company announced it received CE mark approval for its Excelsius3D imaging system. The regulatory clearance permits the company to begin commercial sales of the surgical imaging platform in the European Union and the United Kingdom.

European Expansion

The company's stock rose 1% in extended trading following the announcement. The CE mark is a critical regulatory milestone that signifies a product has met the EU's health, safety, and environmental protection standards, opening a significant new market for Globus Medical.

"The CE mark for Excelsius3D represents an important milestone in the continued expansion of the Excelsius Ecosystem," said Keith Pfeil, President and CEO of Globus Medical, in the company's statement. The system previously received U.S. Food and Drug Administration (FDA) 510(k) clearance in 2021.

System Capabilities

The Excelsius3D is a mobile, 3-in-1 imaging platform that provides:

Ad

• 3D cone-beam computed tomography (CT)
• 2D fluoroscopy
• Digital radiography

A key feature of the system is its integration with Globus Medical’s ExcelsiusGPS robotic navigation system. This allows for the use of intraoperative imaging and robotic navigation within a single, unified surgical workflow. The system can also be used as a standalone imaging device.

Market Implications

For investors, the approval represents a key step in Globus Medical's strategy to grow its international footprint and increase the adoption of its integrated surgical technology. The Excelsius3D system is indicated for procedures where physicians require detailed 2D and 3D imaging of anatomical structures, particularly bony anatomy and metallic objects, in both adult and pediatric patients.